Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: = 99.58%
Targets |
vasopressin V1 receptor
|
---|---|
References |
|
Molecular Formula |
C54H78N16O17S2
|
---|---|
Molecular Weight |
1287.433
|
Exact Mass |
1286.52
|
Elemental Analysis |
C, 50.38; H, 6.11; N, 17.41; O, 21.13; S, 4.98
|
CAS # |
914453-96-6
|
Related CAS # |
Terlipressin diacetate; 1884420-36-3; Terlipressin; 14636-12-5
|
Appearance |
Solid powder
|
SMILES |
CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
|
InChi Key |
BYDVFOPTAIPAGA-LCGYVTRFSA-N
|
InChi Code |
InChI=1S/C52H74N16O15S2.C2H4O2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37;1-2(3)4/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80);1H3,(H,3,4)/t31-,32-,33-,34-,35-,36-,37-,38-;/m0./s1
|
Chemical Name |
acetic acid;(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
|
Synonyms |
Gly-Gly-Gly-8-Lys-vasopressin; TGLVP; triglycyl lysine vasopressin; Terlipressin; Terlipressin acetate; trade names: Glypressin; Teripress
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7767 mL | 3.8837 mL | 7.7674 mL | |
5 mM | 0.1553 mL | 0.7767 mL | 1.5535 mL | |
10 mM | 0.0777 mL | 0.3884 mL | 0.7767 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04460560 | Active Recruiting |
Drug: Terlipressin | Hepatorenal Syndrome | University of Pennsylvania | December 11, 2020 | Phase 3 |
NCT05170230 | Recruiting | Drug: Terlipressin | Myoma | Wael Elbanna Clinic | February 27, 2022 | Not Applicable |
NCT05242783 | Recruiting | Drug: Terlipressin | Myoma | Wael Elbanna Clinic | February 1, 2022 | Not Applicable |
NCT05154279 | Recruiting | Drug: Terlipressin | Laparoscopic Myomectomy | Wael Elbanna Clinic | February 27, 2022 | Not Applicable |
NCT04961528 | Recruiting | Drug: Terlipressin Drug: Placebo Drug: Tranexamic Acid 500 MG |
Hemoptysis | Assistance Publique - Hôpitaux de Paris |
March 27, 2022 | Phase 3 |
Forest plot showing the difference in the control of bleeding in patients treated with terlipressin compared with no vasoactive drugs. Medicine (Baltimore) . 2018 Nov;97(48):e13437. td> |
Forest plot showing the difference in the rebleeding in patients treated with terlipressin compared with balloon tamponade. Medicine (Baltimore) . 2018 Nov;97(48):e13437. td> |
The effect of Terlipressin on the overall mouse hepatic blood perfusion in vivo. Oncotarget . 2016 Oct 25;7(43):69276-69290. td> |
Terlipressin treatment ameliorates hepatic injury and inflammation. Oncotarget . 2016 Oct 25;7(43):69276-69290. td> |
Changes in IEC-6 cell viability following OGD/R. (A) Effect of different concentrations of terlipressin on IEC-6 cell viability following OGD/R. Exp Ther Med . 2017 Jul;14(1):260-266. td> |